Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MRNA News 15 January 2026 - 26 January 2026

Moderna (MRNA) stock slips; Feb. 13 earnings call is the next catalyst for the share price

Moderna (MRNA) stock slips; Feb. 13 earnings call is the next catalyst for the share price

New York, Jan 26, 2026, 16:37 EST — After-hours Moderna, Inc. shares closed Monday down 1.5% at $47.98. In after-hours trading, which follows the 4 p.m. close, the stock held steady around $47.99. (Investing.com) The vaccine maker announced Monday it will release its fourth-quarter 2025 results on Feb. 13, followed by a conference call and webcast at 8 a.m. ET. Executives are set to provide a corporate update during the session. (ACCESS Newswire) Investors are now eyeing that date as the next key checkpoint to assess how rapidly Moderna can stabilize both revenue and expenses while shifting focus beyond its
26 January 2026
·····
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

New York, Jan 24, 2026, 06:23 EST — Market closed Moderna shares dropped on Friday following a volatile week, as investors absorbed the company’s caution about mounting U.S. political and regulatory challenges affecting its vaccine development funding. The pullback is significant as Moderna aims to prove it can outgrow its shrinking COVID franchise while funding a costly pipeline. The CEO’s remarks this week highlighted policy risks alongside clinical ones, at a moment when traders have been swift to either snap up or sell off the stock. (Reuters) U.S. markets remain closed for the weekend, leaving Monday’s session to reveal if
24 January 2026
····
Merck (MRK) stock price slips into the weekend — what investors watch next week

Merck (MRK) stock price slips into the weekend — what investors watch next week

New York, Jan 23, 2026, 21:46 (EST) — The market is closed. Merck & Co shares ended Friday down 0.92%, closing at $108.18. In after-hours trading, the stock slipped slightly to $107.91. (Yahoo Finance) U.S. markets remain closed until Monday, leaving investors to focus on Merck’s upcoming fourth-quarter and full-year earnings report on Feb. 3. The company’s executives will also hold a conference call that day. (Merck.com) Policy uncertainty around vaccines is now front and center. Under Health Secretary Robert F. Kennedy Jr., the U.S. has overhauled inoculation schedules and guidelines, Reuters reported. Analysts say these moves could hit demand
24 January 2026
·····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

New York, January 23, 2026, 14:26 EST — Regular session Pfizer (PFE.N) shares dropped roughly 1.9% to $25.62 Friday afternoon, underperforming the health-care sector as the stock went ex-dividend. The Health Care Select Sector SPDR Fund (XLV) dipped about 0.5%, while the SPDR S&P 500 ETF Trust (SPY) inched up around 0.1%. Merck (MRK.N) slipped about 1%, and Moderna (MRNA.O) tumbled over 7%. Trading volume for Pfizer hit roughly 24.8 million shares. The timing is largely mechanical. The ex-dividend date marks the first trading day when a stock no longer includes the upcoming dividend — if you buy the stock
23 January 2026
·······
Moderna stock slides nearly 6% as CEO flags pullback in Phase III vaccine trials

Moderna stock slides nearly 6% as CEO flags pullback in Phase III vaccine trials

New York, Jan 23, 2026, 12:45 EST — Regular session Moderna (MRNA.O) shares slipped 5.8%, hitting $48.88 by midday Friday, after fluctuating between $46.86 and $50.95 earlier. Roughly 10.9 million shares traded hands. The pullback is crucial as the company pitches its next revenue driver amid fading demand for COVID-19 vaccines. Vaccine politics have also shifted from a background concern to an active risk for the stock. Changes in U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. have unsettled investors and industry leaders, Reuters reported, putting pressure on vaccine-focused stocks. Stephen Farrelly, global pharma and healthcare lead at
23 January 2026
···
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

New York, January 22, 2026, 18:46 EST — After-hours Moderna shares surged 4.2% to $51.87 in after-hours trading Thursday, following an earlier jump of about 11% to $55.17 on heavy volume—more than 34 million shares changed hands. CEO Stephane Bancel told Bloomberg TV the company won’t invest in new late-stage (Phase 3) vaccine trials, pointing to growing resistance from U.S. officials. He cautioned that the U.S. market is becoming less dependable. “You cannot make a return on investment if you don’t have access to the U.S. market,” Bancel said. (Reuters) Moderna’s pivot comes amid slumping demand for its COVID vaccines
23 January 2026
····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

New York, Jan 22, 2026, 10:15 EST — Regular session Moderna shares climbed 7.7% to $53.65 Thursday morning, extending gains fueled by fresh long-term data on its experimental personalized cancer vaccine, created in partnership with Merck. Moderna’s push is vital as it aims to convince investors it can thrive beyond COVID vaccines. A promising mid-stage oncology trial could swiftly shift investor sentiment. Wall Street opened sharply higher after President Donald Trump softened his stance on tariffs targeting European countries. The Dow surged 0.81%, and the S&P 500 climbed 0.70% at the start of trading. (Reuters) Moderna and Merck revealed Tuesday
22 January 2026
····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

New York, Jan 22, 2026, 04:51 EST — Premarket. Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session. (Yahoo Finance) The rally followed fresh five-year follow-up data on Moderna’s experimental personalised cancer vaccine used with Merck’s blockbuster immunotherapy Keytruda in high-risk melanoma, the companies said. (Merck.com) The move matters because Moderna is still trying to replace shrinking COVID-19 vaccine revenue with new products. Investors have been quick to reward any sign its mRNA technology can travel well beyond respiratory shots. In the update, the companies said the vaccine-Keytruda combination
22 January 2026
······
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda, its best-selling cancer drug, ahead of competition and cheaper alternatives hitting the market later this decade. The company recently told investors it expects new growth drivers to generate up to $70 billion in revenue by the mid-2030s. (Reuters) Merck managed
21 January 2026
·······
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

New York, January 20, 2026, 14:02 EST — Regular session Merck & Co (MRK.N) shares held steady on Tuesday following news that the company’s personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda (pembrolizumab). By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating between $107.06 and $109.11. (Reuters) Why it matters now: Keytruda stands as Merck’s top-selling drug, with crucial patents set to expire in 2028, tightening the timeline on what comes next for the company. Back in 2022, Merck told Reuters that
20 January 2026
·····
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA

Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA

New York, Jan 17, 2026, 06:02 EST — The market has closed. Moderna’s stock climbed 6.3% Friday, closing at $41.83 as the rally that’s been choppy all week gained traction. Since January 12, shares have surged roughly 24%, boosted by a 17% jump on January 13, followed by a short pullback on January 15. (Investing.com) Investors aren’t focused just on Friday’s headline. They’re sizing up Moderna’s broader challenge: overcoming the post-pandemic drop in COVID vaccine sales and proving it can balance cash flow while advancing new products in late-stage trials. Wall Street will be closed Monday in observance of Martin
17 January 2026
·····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters) The political noise around vaccines is back in focus. Sanofi Chief Executive Paul
15 January 2026
·········
1 2 3 4

Stock Market Today

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
Verizon shares fell 1.7% to $46.31 Friday, ending a seven-session rally and closing about 2.7% below Thursday’s one-year high. The dip follows news that consumer chief Sowmyanarayan Sampath will step down, with Alfonso Villanueva named interim head. Verizon has climbed 16% since January 29 amid strong subscriber growth and a $25 billion buyback plan.
Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

7 February 2026
Cisco shares rose 3% to $84.82 Friday, nearing $85 ahead of fiscal Q2 results due Feb. 11. UBS maintained a Buy rating and $90 target, citing strong product order growth and data-center demand. Investors are watching AI-related spending and U.S. economic data that could affect rates. Peers Fortinet, CrowdStrike, and Palo Alto Networks also gained.
Coherent stock whiplash: COHR jumps after earnings drop — what to watch next week

Coherent stock whiplash: COHR jumps after earnings drop — what to watch next week

7 February 2026
Coherent Corp shares jumped 8.8% to $227.68 Friday, rebounding after a two-day slide following its quarterly results. The company reported December-quarter revenue of $1.69 billion and non-GAAP earnings of $1.29 a share, with datacenter and communications driving 72% of sales. Barclays, Stifel, and JPMorgan raised price targets to $235–$245. FMR LLC disclosed a 15% stake as of Dec. 31.
Go toTop